Chimerix to Announce Fourth Quarter and Full Year

DURHAM, N.C., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX ), a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant, unmet medical needs, today announced that it will host a live conference call and audio webcast on Thursday, March 2, 2017 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2016, and to provide a business overview.

To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 77533539. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com . An archived webcast and accompanying slides will be available on the Chimerix website approximately two hours after the event.

About Chimerix Chimerix is a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant, unmet medical needs. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com .

CONTACT: Investor Relations: ir@chimerix.com or Will O’Connor Stern Investor Relations Will@sternir.com 212-362-1200 Media: Becky Vonsiatsky W2O Group bvonsiatsky@w2ogroup.com 413-478-2003